IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS Limited (IONTAS), a leader in antibody discovery and optimization of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

Under the terms of the agreement, IONTAS will initially apply its proprietary technologies to provide Teva with a panel of optimised antibodies against a defined target. Teva will have the option to enter into further optimisation programmes in the future. The agreement also includes options for the screening of biophysical properties suitable for developable antibodies.

Dr John McCafferty, Founder and Chief Executive Officer of IONTAS, commented:

Our experience in both antibody discovery and optimisation enables us to generate antibodies that meet the stringent characteristics required by our Partners and the selection of IONTAS by Teva is a validation of this know-how and expertise. With our ability to focus on function, affinity, specificity and developability we can generate lead antibodies with lower risk of Chemistry, Manufacturing and Controls issues.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    IONTAS. (2019, July 31). IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement. News-Medical. Retrieved on October 17, 2019 from https://www.news-medical.net/news/20190731/IONTAS-and-Teva-Pharmaceuticals-announce-new-antibody-optimization-agreement.aspx.

  • MLA

    IONTAS. "IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement". News-Medical. 17 October 2019. <https://www.news-medical.net/news/20190731/IONTAS-and-Teva-Pharmaceuticals-announce-new-antibody-optimization-agreement.aspx>.

  • Chicago

    IONTAS. "IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement". News-Medical. https://www.news-medical.net/news/20190731/IONTAS-and-Teva-Pharmaceuticals-announce-new-antibody-optimization-agreement.aspx. (accessed October 17, 2019).

  • Harvard

    IONTAS. 2019. IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement. News-Medical, viewed 17 October 2019, https://www.news-medical.net/news/20190731/IONTAS-and-Teva-Pharmaceuticals-announce-new-antibody-optimization-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post